Pre-MENACTRIMS Symposium Paradigms
From Signals to Decisions: Technological, Imaging and Fluid Biomarkers in MS Treatment
Multiple sclerosis care increasingly requires information beyond clinical
assessment alone. With growing recognition of subclinical disease activity,
smouldering inflammation and progression independent of relapse activity,
sensitive and clinically meaningful biomarkers are becoming increasingly
important.
The Paradigms pre-MENACTRIMS symposium will explore how technological,
imaging and fluid biomarkers can provide complementary insights into disease
activity, treatment response and progression. It will examine how digital
tools capture real-world function, how advanced imaging reveals inflammatory
and neurodegenerative processes, and how fluid biomarkers such as
neurofilament light chain can detect biological changes not always apparent
clinically.
A central theme will be how these different sources of information can be
integrated with clinical judgement and patient characteristics to support
more precise and personalised treatment decisions in MS care.
Program
|
From Signals to Decisions: Technological, Imaging and Fluid Biomarkers in MS Treatment
Chair: Bassem Yamout, President of MENACTRIMS (UAE)
|
||
| 13:45–14:00 | Registration | |
| 14:00–14:05 | Welcome |
Bassem Yamout (UAE) & Celia Oreja-Guevara (ES) |
| 14:05–14:20 | Technological Biomarkers | Tjalf Ziemssen (DE) |
| 14:20–14:35 | Imaging Biomarkers | Celia Oreja-Guevara (ES) |
| 14:35–14:50 | Fluid Biomarkers | Melinda Magyari (DK) |
| 14:50–15:00 | Q&A and Panel Discussion | All Faculty |
Faculty
Target Audience
- Specialists
- Neurologists
- Practitioners
- Researchers in the field of MS
Registration
Registration is complimentary but mandatory and can be completed via the online registration module upon registering for the congress pass.
What are the key takeaways from this Symposium?
By the end of the symposium, participants should be able to:
- Understand how technological, imaging and fluid biomarkers can support more personalised treatment decisions in multiple sclerosis.
- Identify biomarker signals that may help detect subclinical disease activity, treatment response and risk of progression.
- Explore how digital and wearable technologies can complement clinic-based assessment by capturing real-world function over time.
- Recognise the imaging and fluid biomarkers with the greatest potential relevance for monitoring inflammation, neurodegeneration and smouldering disease.
- Consider the limitations, confounders and standardisation challenges that may affect biomarker interpretation and implementation in clinical practice.
- Integrate biomarker information with clinical judgement, MRI findings, patient characteristics and treatment goals, while considering applicability across different healthcare settings.
elaboration of the presentations.
